Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Emerging HER2-Targeted TKIs in Lung Cancer: Navigating the New Frontier in Precision Oncology
June 23, 2025
View More
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Medical Crossfire®: Starting at the Front Line in Metastatic Pancreatic Cancer – As New Options Emerge, How Do You Select and Sequence?
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Bloodstream Infections in Ethiopia Reveal High Rates of Multidrug Resistance and Fungal Involvement
At ASM Microbe 2025, a cross-sectional study highlights Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.
Considering the Impact of Crop Spraying and Antifungal Resistance
June 20th 2025At the ASM Microbe conference, Mike Bromley, PhD, offers some insights on the importance of a One Health approach addressing the growing antifungal resistance to azoles and Aspergillus fumigatus because of the connection between crop spraying and the rise of resistance.
CDC Reverses Layoffs, Restores Critical Hepatitis and STI Labs Amid Public Health Concerns
After initially closing its viral hepatitis and sexually transmitted disease laboratories, the CDC rescinds staff terminations, preserving vital disease surveillance and outbreak response capabilities.
A Passion for Infectious Disease Education and Communication
June 16th 2025In our latest podcast, Tim Gauthier, PharmD, BCPS, BCIDP, discusses all things pathogens and antibiotics. He also details the opportunities presented for antimicrobial stewardship when it combines diagnostics and treatment duration.
Professional Societies Must Address Gaps When Politics Overrides Evidence
June 16th 2025In an early release of his letter for the Summer issue, Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the recent changes to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), and where professional societies must step in and lead with research data and clinical guidance in the absence of experienced committee members.
FDA Expands Indication for AbbVie’s Antiviral as First Treatment for People With Acute Hepatitis C
June 13th 2025The antiviral, glecaprevir/pibrentasvir (Mavyet), is the first and only oral 8-week pangenotypic treatment approved for people with acute or chronic hepatitis C. The approval supports global clinical guidelines to advance testing and treatment of HCV regardless of chronicity and supports public health goals for disease elimination.
The Lingering Threat: Managing Severe COVID-19 in the Postpandemic Era
June 12th 2025Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.